NCT07185932View on ClinicalTrials.gov

Efficacy and Safety of Rifaximin in Treating MAFLD

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 10, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Metabolic-associated Fatty Liver Disease
Interventions
DRUG

Rifaximin (Xifaxan)

Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks.

Trial Locations (1)

200003

RECRUITING

Changzheng Hospital, Naval Medical University, shanghai, China, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER